US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

3.00

-0.0200-0.66%

Post-market: 3.030.0300+1.00%19:49 EDT

Volume:792.16K

Turnover:2.43M

Market Cap:163.22M

PE:-0.36

High:3.20

Open:3.05

Low:2.98

Close:3.02

Loading ...

Overview Company News Filings

Alumis price target lowered to $15 from $19 at H.C. Wainwright

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

THOMSON REUTERS

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026

Alumis Inc - Phase 3 Onward Program Ongoing With Topline Data Expected in Q1 2026

THOMSON REUTERS

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating

Sector Update: Health Care Stocks Lower Tuesday Afternoon

MT Newswires Live

Acelyrin Reaffirms Merger Deal With Alumis

MT Newswires Live

REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer

Alumis Inc. Announces Merger with ACELYRIN, Inc.

BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

THOMSON REUTERS

Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALMS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":3,"timestamp":1751313600000,"preClose":3.02,"halted":0,"volume":792159,"hourTrading":{"tag":"盘后","latestPrice":3.03,"preClose":3,"latestTime":"19:49 EDT","volume":8547,"amount":25627.3308,"timestamp":1751327379399},"delay":0,"floatShares":8664240,"shares":54405544,"eps":-8.309579,"marketStatus":"Closed","change":-0.02,"latestTime":"06-30 16:00:00 EDT","open":3.05,"high":3.195,"low":2.9823,"amount":2426757.8666387997,"amplitude":0.07043,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.309579,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751356800000},"marketStatusCode":5,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":3.02,"preHourTrading":{"tag":"盘前","latestPrice":3.13,"preClose":3.02,"latestTime":"09:24 EDT","volume":1134,"amount":3519.1327878,"timestamp":1751289890604},"postHourTrading":{"tag":"盘后","latestPrice":3.03,"preClose":3,"latestTime":"19:49 EDT","volume":8547,"amount":25627.3308,"timestamp":1751327379399},"volumeRatio":0.689678,"impliedVol":2.2132,"impliedVolPercentile":0.5893},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":8664240,"roa":"-101.07%","roe":"-247.05%","lyrEps":-10.381567,"volumeRatio":0.689678,"shares":54405544,"dividePrice":0,"high":3.195,"amplitude":0.07043,"preClose":3.02,"low":2.9823,"week52Low":2.7601,"pbRate":"0.97","psRate":"9.39","week52High":13.53,"institutionHeld":0,"latestPrice":3,"eps":-8.309579,"divideRate":0,"volume":792159,"delay":0,"ttmEps":-8.309579,"open":3.05,"prevYearClose":7.86,"prevWeekClose":3.02,"prevMonthClose":3.5,"prevQuarterClose":6.14,"fiveDayClose":2.8,"twentyDayClose":3.5,"sixtyDayClose":9.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520431796","title":"Alumis price target lowered to $15 from $19 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2520431796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520431796?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:10","pubTimestamp":1742465439,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-15-from-19-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-15-from-19-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2520019878","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520019878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520019878?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA7CCKHR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2520933601","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520933601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520933601?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414700,"startTime":"0","endTime":"0","summary":"– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated;","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU2028103732.USD","LU1989772840.SGD","LU0106261372.USD","BK4135","BK4534","BK4516","LU0106831901.USD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU2133065610.SGD","LU0912757837.SGD","LU1732799900.SGD","LU0158827781.USD","LU2089284900.SGD","LU2357305700.SGD","LU0098860793.USD","LU2023251221.USD","LU2089283258.USD","LU0267386448.USD","BK4581","BK4127","LU1548497426.USD","LU2111349929.HKD","LU1162221912.USD","IE00BKVL7J92.USD","BK4007","LU0971096721.USD","LU1732800096.USD","LU2271345857.HKD","LU1720051108.HKD","LU1668664300.SGD","LU1989772923.USD","BK4588","LU0795875086.SGD","CNS","BK4504","LU0795875169.SGD","LU1074936037.SGD","LU0314104364.USD","BK4585","LU1363072403.SGD","LU2347655156.SGD","SLE","BK4077","LU0158827948.USD","ALMS","LU1720051017.SGD","LU0225283273.USD"],"gpt_icon":0},{"id":"2519350938","title":"Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2519350938","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519350938?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:15","pubTimestamp":1741868100,"startTime":"0","endTime":"0","summary":"Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.Acelyrin said Tang Capital held 8.8% of its outstanding common stock.Tang Capital didn't immediately respond to a request for comment issued through LinkedIn.Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount.Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4139","BK4007","SLRN"],"gpt_icon":0},{"id":"2519887248","title":"ACELYRIN Adopts Limited-Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887248?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 13, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan .The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.The Rights Plan is effective immediately and will expire on March 12, 2026.ACELYRIN stockholders do not need to take any further action at this time.Guggenheim Securities, LLC is serving as financial advisor to ACELYRIN and Fenwick & West LLP and Paul Hastings LLP are serving as its legal counsel.ACELYRIN, INC.  is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commerciali","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-adopts-limited-duration-stockholder-110000068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2518222336","title":"Alumis to Present at Leerink's 2025 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222336","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518222336?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March  10, 2025  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimiz","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039679/0/en/Alumis-to-Present-at-Leerink-s-2025-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","ALMS","BK4007","BK4137"],"gpt_icon":0},{"id":"2518240407","title":"Alumis Price Target Maintained With a $19.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240407?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:49","pubTimestamp":1741607340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:49 ET (11:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2517419854","title":"BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517419854","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517419854?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:07","pubTimestamp":1741442831,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026March 8 (Reuters) - Alumis Inc ALMS.O:ALUMIS INC - PHASE 3 ONWARD PROGRAM ONGOING WITH TOPLINE DATA EXPECTED IN Q1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nFWN3PR08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2517441570","title":"Alumis Inc - Phase 3 Onward Program Ongoing With Topline Data Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517441570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517441570?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:03","pubTimestamp":1741442584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nFWN3PR08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2517744441","title":"Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517744441","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517744441?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:00","pubTimestamp":1741442400,"startTime":"0","endTime":"0","summary":"ESK-001 is a highly selective, next-generation oral tyrosine kinase 2  inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus. Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0. ESK-001 was generally well-tolerated at one year, with no new safety findings. “We’re excited to see that ESK-001 continues to demonstrate a favorable clinical profile for the potential treatment of moderate-to-severe plaque psoriasis, with the ability to improve clinical outcomes as well as patients’ reported symptoms and quality of life,\" said Dr. Jrn Drappa, Alumis’ Chief Medical Officer. \"We believe in the potential of ESK-001 to fill a critical gap in psoriasis patient care as an oral therapy that is well tolerated and may provide biologic-like clinical responses.\". “These long-term data further support the highly differentiated profile of ESK-001 and reinforce its potent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-esk-001-phase-2-140000841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMS","BK4523","BK4007","IFN"],"gpt_icon":0},{"id":"2517959961","title":"Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517959961?lang=en_us&edition=fundamental","pubTime":"2025-03-05 11:45","pubTimestamp":1741146344,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ALMS stock, giving a Buy rating on March 3. Thomas Smith’s rating is b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-alumis-inc-s-clinical-programs-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-alumis-inc-s-clinical-programs-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2517489600","title":"Sector Update: Health Care Stocks Lower Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2517489600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517489600?lang=en_us&edition=fundamental","pubTime":"2025-03-05 03:00","pubTimestamp":1741114825,"startTime":"0","endTime":"0","summary":"Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund  shedding 0.4%.The iShares Biotechnology ETF  rose less than 0.1%.In corporate news, Walgreens Boots Alliance  is nearing the completion of a go-private deal with Sycamore Partners for around $10 billion, The Wall Street Journal reported late Monday. Walgreens shares jumped 7.3%.UnitedHealth Group  shares rose 2.2% after a retired federal judge in her role as special master issued a recommendation favoring UnitedHealth to the presiding federal judge in a lawsuit brought by the US Department of Justice, which accused the healthcare company of failing to return money it received via the Medicare Advantage program.Acelyrin  and Alumis  reaffirmed Tuesday their commitment to merge in an all-stock deal, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication of interest is \"not reasonably expected to result in a superior pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023059063.AUD","LU1267930227.SGD","LU0672654240.SGD","LU0321505439.SGD","LU2491050154.USD","LU2361044949.HKD","UNH","WBA","LU0211328371.USD","LU0234572021.USD","IE00BJJMRX11.SGD","LU0310800379.SGD","LU2552382215.SGD","XLV","IE00BFSS7M15.SGD","LU0557290698.USD","LU2347655156.SGD","LU1267930730.SGD","LU0238689110.USD","LU0417517546.SGD","LU0708994859.HKD","LU2552382058.USD","WBA.AU","LU0316494557.USD","LU0661504455.SGD","LU1551013342.USD","ALMS","LU1778281490.HKD","LU1854103824.USD","LU1506573853.SGD","LU0795875086.SGD","IBB","LU0353189763.USD","LU2236285917.USD","SG9999014906.USD","SLRN","LU0820562030.AUD","LU0823416689.USD","LU1291159041.SGD","LU1988902786.USD","LU0158827781.USD","SG9999014898.SGD","SG9999017495.SGD","LU1548497426.USD","SG9999014914.USD","IE00B19Z3581.USD","LU0211326755.USD","LU1261432733.SGD","LU0683600562.USD","LU1720051017.SGD"],"gpt_icon":1},{"id":"2516608325","title":"Acelyrin Reaffirms Merger Deal With Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608325","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608325?lang=en_us&edition=fundamental","pubTime":"2025-03-04 23:10","pubTimestamp":1741101018,"startTime":"0","endTime":"0","summary":"Acelyrin (SLRN) and Alumis (ALMS) reaffirmed Tuesday their commitment to merge in an all-stock transaction, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SLRN","BK4007","ALMS"],"gpt_icon":0},{"id":"2516067205","title":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516067205","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516067205?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:44","pubTimestamp":1741099479,"startTime":"0","endTime":"0","summary":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offerCorrects company name to \"Concentra\" in bullet 3, corrects typographical error in bullet 5** Shares of dru","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","SEM","ALMS","CON"],"gpt_icon":0},{"id":"2516777456","title":"Alumis Inc. Announces Merger with ACELYRIN, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516777456","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516777456?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:28","pubTimestamp":1741098505,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has shared an update. On March 4, 2025, Alumis Inc. and ACELYRIN, Inc. announced their commitment to merge in an all-stock ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-announces-merger-with-acelyrin-inc-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-announces-merger-with-acelyrin-inc-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2516383674","title":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516383674","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516383674?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:07","pubTimestamp":1741097248,"startTime":"0","endTime":"0","summary":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis MergerMarch 4 (Reuters) - Alumis Inc ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2516674655","title":"Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674655","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674655?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:06","pubTimestamp":1741097208,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biop...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2516748486","title":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516748486","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516748486?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:06","pubTimestamp":1741097191,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed MergerMarch 4 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN REAFFIRM STRATEGIC AND FINANCIAL RATIONALE OF PROPOSED ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA48S77V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516783671","title":"ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516783671","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516783671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA149XQ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRN","BK4007","ALMS"],"gpt_icon":0},{"id":"2516751671","title":"Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516751671","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516751671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":"Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet. LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025  -- ACELYRIN, INC.  and Alumis Inc.  today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.\"The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger,\" said Mina Kim, Chief Executive Officer of ACELYRIN. \"We chose to enter into the merger agreement with Alumis after a comprehensive assessment of strategic alternatives, and believe this is the best outcome for ACELYRIN stockholders. We're excited about the combined company's potential for significant value creation as a result of its expanded portfolio, strong financial foundation and proven leadership.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4139","BK4007","SLRN"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":112,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"ALMS","fiscalQuarterEnding":"2025/03","expectedEps":-1.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.82},{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1749787200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-06-27","current":-0.522906,"percent":0.956175,"low":-4.913756,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"high":-0.443678,"avg":-2.15659,"sd":1.218803,"marketCap":179538295},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295}],"updateTime":1751332837007}}}